The Claim
Ezetimibe is not associated with an increased risk of cancer, new-onset diabetes, fractures, or neurocognitive events when compared to placebo or standard care, as demonstrated by a meta-analysis of 48 randomized controlled trials involving 28,444 participants and 4 observational studies involving 1,667 participants, with relative risks close to 1.0 for all outcomes, supporting its long-term safety profile.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking ezetimibe doesn’t seem to raise your chances of getting cancer, diabetes, broken bones, or brain-related issues, based on a big review of studies that looked at thousands of people over time.
See the scientific wording
Ezetimibe is not associated with increased risk of cancer, new-onset diabetes, fractures, or neurocognitive events compared to placebo or standard care, based on a meta-analysis of 48 randomized controlled trials (n=28,444) and 4 observational studies (n=1,667), with relative risks close to 1.0 for all outcomes, supporting its long-term safety profile.
What the research says
1 studyStudy: Are We Using Ezetimibe As Much As We Should?
The study talks about ezetimibe and says it's safe and well-tolerated, which supports the idea that it doesn’t increase risks like cancer or diabetes.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.